Morgan Stanley Call 200 ABBV 20.0.../ DE000ME7L2D1 /
| 5/13/2024 8:17:54 PM | Chg.0.000 | Bid10:00:33 PM | Ask10:00:33 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.650EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
AbbVie Inc | 200.00 USD | 9/20/2024 | Call |
GlobeNewswire
12:14 AM
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
5/9
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
5/8
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
5/8
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
5/8
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/7
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/2
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...
GlobeNewswire
5/1
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
4/30
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire
4/30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
4/25
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
GlobeNewswire
4/25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
